Gilead, LG Life Sciences in License Deal

Gilead Sciences Inc. and LG Life Sciences Ltd. said Wednesday they entered a license agreement focused on caspase inhibitors for the treatment of fibrotic diseases.
Silicon Valley/San Jose Business Journal